A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care

AstraZeneca58,326 enrolled

Overview

To describe the type II diabetes population in primary care with special reference to treatment, other diseases and mortality during the last decade. To test the hypothesis that the type or combination of per oral glucose lowering drugs have different effects on the risk of cardiovascular disease and diabetic complications.

Study Type

OBSERVATIONAL

Enrollment

58,326

Conditions

Diabetes Type II

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with type II diabetes, according to medical records, diagnosis, prescription or lab assessments Exclusion Criteria: * Patients followed by physician for less than 6 months after diagnosis of Diabetes type II

Locations (1)

Research Site

Uppsala, Sweden

Outcomes

Primary Outcomes

Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality

Time frame: The endpoints will be extracted from the medical records on one occassion, covering a period of one decade.

Secondary Outcomes

Retinopathy, renal failure, hypoglycaemic episodes, other diabetic complications

Time frame: The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.

Time from: Metformin (MET) to Insulin (INS) versus Metformin (MET) -> Metformin (MET)+Sulfonylurea (SU) ->Insulin (INS)

Time frame: The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.

Number of consultations in primary care. Number of hospitalisations

Time frame: The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.